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Abstract
Background: The recent discovery of the Merkel cell polyomavirus and its consistent association with Merkel cell
carcinoma has drawn attention to the numerous recently discovered polyomaviruses and their possible involvement in
the etiopathogenesis of non-melanoma skin cancer (NMSC). Data on the recently discovered human polyomavirus 6
(HPyV6) and its role in NMSC are sparse and in part controversial.
Methods: In the present study we tested a large number (n = 299) of NMSC specimens for the presence of
human polyomavirus 6 (HPyV6) by DNA PCR and HPyV6 fluorescence in situ hybridization (FISH). In detail, 59
keratoacanthomas (KA), 109 basal cell carcinomas (BCC), 86 squamous cell carcinomas (SCC) and 45
trichoblastomas (TB) were tested for the presence of HPyV6.
Results: HPyV6 DNA PCR and subsequent sequence analysis revealed that 25 KAs (42.3 %), 23 BCCs (21.1 %),
8 SCCs (9.3 %) and 10 TBs (22.2 %) were HPyV6 positive. The presence of HPyV6 DNA was visualized and
validated on the single cell level within the histomorphological context by HPyV6 fluorescence in situ
hybridization.
Conclusions: The high frequency of HPyV6 DNA in 42.3 % of KA possibly points to a role for HPyV6 in the
etiopathogenesis of KAs. Although the detection rate of HPyV6 DNA in BCCs and TBs is within the previously
reported detection range in normal skin, it does not exclude a possible role for HPyV6 in the carcinogenesis
in a significant subset of these skin tumors.
Keywords: Human Polyomavirus 6, HPyV6, Keratoacanthoma, Non melanoma skin cancer, Fluorescence in situ
hybridization, FISH
Background
Non melanoma skin cancer (NMSC) constitutes the
most common group of human cancers and still its inci-
dence is continuously rising [1, 2]. However, the under-
lying etiology and molecular pathogenesis of NMSC
remains in large part unresolved. Immune senescence
and immunosuppression have been identified as import-
ant risk factors in the pathogenesis of NMSC [3, 4],
clearly pointing to a possible involvement of an infec-
tious agent in NMSC etiology. In large epidemiological
studies, an increased risk of cutaneous human papillo-
mavirus (HPV) and cutaneous squamous cell carcinoma
(SCC) was shown in the general population and im-
munosuppressed organ transplant recipients [5]. It was
shown that the risk to develop squamous cell carcinoma
(SCC), but not basal cell carcinoma (BCC) is associated
with seropositivity for HPV [6]. Although the prevalence
of the main HPV types found, i.e. β-HPV types 5 and 8
ranged between 27 and 85 % [7], they have been dis-
cussed as a possible co-factor in the early onset of cuta-
neous SCC, in combination with UV-induced DNA
damage or immunosuppression [7]. Next to HPV, 13
human polyomaviruses (HPyV) are known (reviewed in
[8, 9], of which 11 have been recently identified in neo-
plastic and non-neoplastic skin samples [10–14] and in
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other patient materials [9, 15–18]. Yet, no conclusive
data for a role of the continuously growing number of
human polyomaviruses in NMSC are available. Ever
since their first detection, HPyV have repeatedly been
incriminated with the etiopathogenesis of human can-
cers. However, only the recently discovered Merkel cell
polyomavirus (MCPyV) has been identified as a new
human tumor virus which is based on the consistent de-
tection of integrated MCPyV DNA in the majority of
Merkel cell carcinomas (MCC), a highly malignant
NMSC [10–12]. In addition, tumor specific mutations
within the large T antigen (LTag) of MCPyV are found in
MCCs [13].
In 2010, human polyomavirus 6 (HPyV6) was isolated
from skin swabs of healthy patients and characterized,
but yet could not be linked to the pathogenesis of any
human disease [14]. Although seroprevalence indicates
that HPyV6 infection is common in adults, ranging from
69 to 76 % [14, 19, 20], it is detected in skin swabs of
normal skins only between 14.3 and 27.6 % [14, 21].
Studies reporting the presence of HPyV6 DNA in NMSC
are sparse [22–25], and in part controversial [21, 26, 27]
(Table 1). Recently, a case of a keratoacanthoma (KA)
which developed during treatment with Vemurafenib in
a BRAF V600E positive melanoma patient was tested
positive for the presence of HPyV6 [28] with pro-
nounced viral load. In the present study we assessed the
presence of HPyV6 DNA in a large number of NMSC
specimens (n = 299), using HPyV6 DNA-PCR. In
addition, we were able to visualize and validate the pres-
ence of HPyV6 DNA on the single cell level in a subset
of HPyV6 DNA positive KAs, BCCs and SCCs by using
fluorescence in situ hybridization (FISH).
Methods
Patients and tissues
Formalin-fixed and paraffin-embedded (FFPE) tissues of
299 skin excisions or biopsies were included in this
study. All respective samples had been excised for diag-
nostic and/or therapeutic reasons. 51 BCC, 29 KA and
86 SCC were obtained from the Maastricht Pathology
Tissue Collection (MPTC) and 58 BCC, 30 KA and
45 TB were obtained from the Center for Dermato-
pathology, Freiburg, Germany.
DNA extraction
First, an H&E stain of the selected specimens was
reviewed by four experienced pathologists (A.z.H., V.W.
C.D., W.W.) to select paraffin material containing >95 %
tumor tissue. Two consecutive 5 μm thick paraffin sec-
tions from each specimen were subjected to DNA ex-
traction. In brief, after deparaffinization, the tissues were
lysed by proteinase K overnight (56 °C) until complete
tissue lysis, and DNA was extracted using the DNeasy
Tissue kit (Qiagen). Purified DNA was measured in a
spectrophotometer (Nano-drop, 2000, Thermo Scien-
tific) and directly used for PCR. DNA quality and
Table 1 Summary of clinicopathological data and results of molecular investigation of non melanoma skin cancer
References Tumor type HPyV6 DNA Detection Methode HPyV6 IHC 6V32 HPyV6-FISH Clinical Data
Schowalter et al. [14] NS (n = 35) 14,3 % DNA-PCR NA NA IC
Ser (n = 65) 69 % VP1 ELISA NA
Duncavage et al. [22] MCC (n = 28) 3,5 % rt-PCR NA NA NA
Schrama et al. [24] SCC (n = 21) 38 % qPCR NA NA NA
BCC (n = 18) 5,5 %
MCC (n = 20) 10 %
Scola et al. [25] SCC (n = 52) 4 % rt-PCR NA NA IC
BCC (n = 41) 7 %
KA (n = 42) 5 %
Imajoh et al. [23] NS (n = 34) 8,8 % rt-PCR NA NA NA
SCC (n = 63) 3,2 %
BCC (n = 50) 2 %
Nicol et al. [19] Ser 37,5 % pos. (age 1–4) VP1 ELISA NA NA IC
61,8 % pos. (age 15–19)
67,1 % pos (age 30–38)
98,2 % pos. (age 80+)
Schrama et al. [28] KA (n = 4) 25 % rt-PCR KA 1/4 (25 %) NA IS
IS immunosuppressed, IC immunocompetent, PCR polymerase chain reaction, IHC immunohistochemistry, FISH fluorescence in situ hybridisation, rt-PCR real time
PCR, qPCR quantitative PCR, ELISA enzyme-linked immunosorbent assay, HPyV6 human polyomavirus 6, NS normal skin, Ser serum, SCC squamous cell carcinoma,
BCC basal cell carcinoma, KA keratoacanthoma, MCC Merkel cell carcinoma, NA not applicable
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integrity was assessed by specimen control size (SCS)
ladder as described [29].
HPyV6 DNA-PCR
PCR was performed with 150 ng of genomic DNA using
the AmpliTaq Gold (Roche) DNA polymerase in a final
volume of 50 μl. For detection of HPyV6, primer sets
and PCR conditions were used as described earlier [14].
Water instead of DNA template was used for PCR-
negative controls containing all other PCR components.
HPyV6 DNA sequence analyses
PCR products were submitted to automated nucleotide
sequencing in an ABI 3130XL genetic analyzer (ABI).
DNA sequences were compared and analyzed with the
reference sequences of the National Center for Biotech-
nology Information (NCBI) Entrez Nucleotide Database
gb gb|HM011563.1| (HPyV6 isolate 627a) and
gb|HM011561.1| (HPyV6 isolate 607b) using the NCBI
Blast program. Multiple sequence alignments were per-
formed with Clustal omega (EMBL-EBI-2014).
Detection of HPyV6 by fluorescence in situ hybridization
(FISH)
FISH was performed as described earlier [30–32]. In
brief, deparaffinized 3 μm thick tissue sections were pre-
treated with 0.2 M HCl, incubated with 1 M NaSCN and
digested with 0.5 mg/ml pepsin (2500–3500 U/mg,
Sigma Chemical, St. Louis, MO). The digoxigenin la-
belled specific whole genome HPyV6 DNA probe was
generated by Nick translation from the pHPyV6-607
(gift from Christopher Buck Addgene plasmid # 24727)
and added to the samples in a hybridization mixture,
containing a concentration of 5 ng/μl, followed by
denaturation of probe and tissue DNA (5 min, 80 °C)
and hybridization overnight (37 °C, humid chamber,
Thermobrite, Abbott, IL). Unbound HPyV6 DNA probe
was stringently washed away. Bound probe was detected
by sequential incubation of the following secondary
antibody conjugates: Rhodamine-labeled sheep anti
digoxigenine antibody (1:100; Roche, Basel, Switzerland)
and Texas red-labeled donkey anti sheep secondary anti-
body (Brunschwig Chemie, Amsterdam, Netherlands).
Prior to incubation, aspecific binding sites where
blocked with Boehringer Blocking reagent (Roche). Cell
nuclei were counterstained with 4.6-diamidino-2-pheny-
lindole dihydrochloride (DAPI; 0.2 μg/ml, Vectashield,
Vector Laboratories, CA). Signals were visualized using
a DM 5000B fluorescence microscope (Leica, Wetzlar,
Germany) coupled to an digital camera (Leica DC 300
Fx) for independent evaluation of FISH signals by 4 in-
vestigators (AzH, AMH, EJS, DR) according to criteria
described earlier [31, 33].
Results
HPyV6-DNA PCR
The DNA quality and integrity of extracted genomic
DNA was assessed by specimen control size (SCS) lad-
der analysis (Fig. 1a) as described earlier [29]. All sam-
ples included in this study revealed sufficient DNA
quality in order to test for HPyV6 by DNA PCR (Fig. 1a).
HPyV6 DNA-PCR directed against the large T antigen
(LTAg) of the HPyV6 genome revealed specific PCR
products in 25/59 (42.3 %) of KA (Fig. 1b), 8/86 (9.3 %)
of SCC, 23/109 (21.1 %) of BCC, and 10/45 (22.2 %) of
TB. All PCR products were sequenced and confirmed
the presence of HPyV6, revealing only minor nucleotide
changes (<2 %).
HPyV6-FISH
In total, 26 KA were tested by HPyV6 FISH, including
13 HPyV6 DNA PCR positive cases and 13 negative
cases. In none of the HPyV6 DNA negative KA specific
HPyV6 fluorescence signals were found in the tumor cell
nuclei. Out of 13 HPyV6 DNA positive KA, 8 (61.5 %)
showed specific positive signals in the HPyV6 FISH.
HPyV6 FISH hybridization signals were restricted to the
mid- and upper epithelial layers of the KAs (Fig. 2a). In
Fig. 1 2 % agarose gel showing the specimen control size (SCS) ladder HPyV6 DNA-PCR and SCS ladder for keratoacanthoma (KA), results HPyV6 DNA-
PCR: a reveals adequate DNA quality of KA in order to proceed with HPyV6 testing. b HPyV6 DNA PCR results of selected KA, showing amplification of
the 123 bp fragment of the VP1 gene (123 bp) while using the primers according to Schowalter et al. [12] with the 123 pb positive controle.
c Summary of the HPyV6-DNA PCR results on (KA), trichoblastoma (TB), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
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addition to these, specific dot-like signals in the keratin
mass of the tumor (Fig. 2c) were seen. The positive FISH
signals were restricted to the tumor areas, no specific
signals were seen in the adjacent non-neoplastic epider-
mis. In dermal and subcutaneous tissue, specific HPyV6
FISH signals were found in perivascular and periadnexial
lymphocytes (data not shown).
Pretreatment of the slides with DNAse lead to the dis-
appearance of the specific HPyV6 FISH signals thus con-
firming the specificity of the hybridization signals. There
was a highly significant correlation between HPyV6
DNA PCR and HPyV6 FISH results (p = 0.0007; Fisher’s
exact test).
Out of 8 HPyV6 DNA PCR positive SCC, 2 were ana-
lyzed by HPyV6 FISH. In both cases, specific nuclear
HPyV6 hybridization signals were seen within the tumor
cells.
Also 5 of the HPyV6 DNA positive BCCs were sub-
jected to HPyV6 FISH. In 4 out of the 5 HPyV6 DNA
positive cases the presence of HPyV6 DNA was con-
firmed by HPyV6 FISH. HPyV6 FISH revealed the spe-
cific punctate nuclear hybridization pattern within the
basaloid tumor cells (Fig. 3). This specific dot-like pat-
tern was not seen in the adjacent non neoplastic tissues.
Also here we could confirm the specificity of the used
HPyV6 FISH probe by DNAse pretreatment.
Discussion
Although major contributions to the understanding of the
pathogenesis of NMSC have been made in the past de-
cades, the etiology of most NMSC remains elusive. The
discovery of the Merkel cell polyomavirus in 2008 and its
role in the etiopathogenesis of Merkel cell carcinoma has
drawn the attention to the continuously growing number
of newly characterized human polyomaviruses [10–13]
(reviewed in [8]).
In the present study we aimed to comprehensively as-
sess the presence of HPyV6 DNA in a large cohort of
NMSC by testing tumor specimens by HPyV6 DNA
PCR. Previous studies, mainly using rtPCR/qPCR [19,
21–27] (Table 1) in smaller NMSC cohorts revealed
variable positivity for HPyV6 in diverse types of NMSC
with varying viral copy numbers, suggesting no evident
pathological role of HPyV6 in NMSC. It is of interest
that by using HPyV6 DNA PCR in this study we were
able to detect more HPyV6 DNA positive NMSC as
previously reported (Table 1). In addition, we established
an HPyV6-specific FISH on formalin fixed and paraffin
Fig. 2 Photomicrographs of a representative example of the presence of HPyV6 detected by FISH in a keratoacanthoma: a DNA sequence
nuclear hybridization signals in the keratinocytes of the lesion (red), located mainly in the middle and upper epidermis (scale bar 30 μm). b HE
staining of keratoacanthoma used for HPyV6 FISH. c DNA sequence nuclear hybridization signals with dot-like specific positivity in the keratin layer
of the lesion (red) (scale bar 30 μm). d overlay DAPI staining of nuclei of keratinocytes (blue) of the area of the lesion shown in C, showing no
nuclei in the keratin layer with the positive FISH signals
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embedded material. The HPyV6 FISH enabled us to
visualize the HPyV6 DNA on the single cell level within
the histomorphological context of the diverse types of
NMSCs.
Yet, the HPyV6 status of KA had solely been investi-
gated in one larger study of 42 cases, showing only 2
positive cases (5 %) [25]. The underlying explanations
for the obviously discrepant results with the present of
HPyV6 prevalence in KA is difficult to understand. It
seems unlikely that the difference is due to technical rea-
sons since in the other study qPCR was used, which has
been shown to provide a comparable sensitivity as the
DNA PCR used in the present study. Most likely the se-
lection of the targeted sequence of the HPyV6 genome
impacts the detection rate of HPyV6 in these skin le-
sions. In this study we used primers targeting the LTAg
region of HPyV6, according to Schowalter et al. [14].
Duncavage et al. [22] used three different qPCR target-
ing two times different regions of the LT-AG and one
time the VP1 region, Schrama et al. [24] used qPCR tar-
geting the LTAg, Imajoh et al. [23] used qPCR targeting
the LTAg and the VP3 region and Schrama et al. [28]
used pPCR targeting the VP3 region.
Of interest, Schrama et al. [28] investigated the pres-
ence of HPyV6 in Vemurafenib induced epithelial prolif-
erations. Vemurafenib is a BRAF-specific inhibitor used
in the therapy of BRAF mutated melanoma patients
(reviewed in [34]). The authors reported a HPyV6 posi-
tive KA, which developed under Vemurafenib therapy in
a BRAF V600E positive melanoma patient, with a pro-
nounced viral load. Since multiple studies have reported
that KA and SCC are one of the most frequent severe
adverse side effects due to Vemurafenib this is of par-
ticular interest (reviewed in [35]). It has recently been
described that HPV can cooperate with Vemurafenib to
promote the initiation of some cutaneous tumors [36],
which basically might be postulated for HPyV6 in KAs
as well. Furthermore, KA frequently occur and relapse
under immunosuppression [4], which relates the occur-
rence of these tumor to an impaired immune system.
The high prevalence of HPyV6 in KA in our study may
point to HPyV6 playing a pathogenic role in the devel-
opment of cutaneous malignancies in the context of im-
mune suppression or immune senescence. This is
indirectly supported by the rather infrequent finding of
HPyV6 in other NMSC.
The HPyV6-specific FISH hybridization pattern in KA,
i.e. its presence in mid- and upper epithelial part and
within the keratine layer, resembles a pattern which has
previously been described for some human papilloma vi-
ruses (HPV) in skin tumors [37]. It has been shown that
HPV DNA is commonly found in superficial layers of
skin tumor lesions, but is not necessarily present
throughout the whole tumor [38]. This may contribute
to a low viral load in the proliferative active cells. During
maturation of these cells the viral load increases and ex-
ceeds the detection limit, becoming detectable in the
superficial layers of the tumor lesion.
Also the HPyV6 status in SCC has recently been inves-
tigated in 3 different studies, reporting a broad variation
in positivity, ranging between 3.2 % [23] and 38 % [24].
In all the three studies rtPCR/qPCR was used to detect
HPyV6 DNA. In the present study, 9.3 % of tested SCC
were positive for HPyV6. These values are closer to the
data of Scola et al. [25] and Imajo et al. [23] who found
HPyV6 DNA in 3.2 and 4 % of the SCC samples. In
comparison with the other tumors we investigated, the
prevalence of HPyV6 in SCC is rather low, lower [14] or
comparable [23] to the prevalence of HPyV6 in normal
skin, suggesting no pathological role in the development
of SCC in immune competent patients.
The prevalence of HPyV6 in BCC is of interest be-
cause three different studies reported HPyV6 positivity
ranging between 2 % [23] and 7 % [25]. In all these stud-
ies the presence of HPyV6 was assessed by qPCR,
whereas we used the HPyV6 DNA PCR according to
Schowalter et al. [14]. Beside BCC, we also tested HPyV6
in TB which yet had not been done before. TB are be-
nign neoplasms of follicular differentiation, which share
several histomorphological features with nodular BCC,
Fig. 3 Photomicrographs of a representative example of HPyV6 detected by FISH in BCC: a Nuclear HPyV6 DNA hybridization signals in the
epithelial tumor cells of a BCC (red), DAPI staining the nuclei (scale bar 30 μm). b Magnification of the marked quadrangular area in a. c HE
staining of BCC used for HPyV6 FISH detection (scale bar 30 μm)
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thus hampering the ease of histomorphological diagnos-
tics in certain circumstances [39]. In our study 21.1 % of
BCC and 22.2 % of TB were shown to harbor HPyV6
DNA. A study [14] using HPyV6 DNA PCR, showed
that skin swabs of healthy donors were in 14.3 % positive
for HPyV6 DNA. This may suggest that the choice of
the target sequence used in qPCR might contribute to
the different results in comparison to our findings,
generated by using conventional DNA PCR. To validate
these positive results we combined the HPyV6 DNA
PCR with HPyV6 FISH also in BCC and found HPyV6
specific hybridization signals within the BCC tumor cells
(Fig. 3).
Conclusions
We demonstrate the presence of HPyV6 DNA in a large
cohort of NMSC by PCR and HPyV6 FISH. The intro-
duction of an HPyV6-specific FISH on FFPE tissues is a
powerful tool to analyze the presence of HPyV6 DNA
on the single cell level within the histomorphological
context. We identified HPyV6 frequently in KA, and in a
significant subset of BCC and TB and to a far lesser
extent in SCC. The significant association with KA is
remarkably, as the virus reveals a distribution pattern
that has been described for pathogenic HPV infection in
skin tumors. The high frequency of HPyV6-DNA in
42.3 % of KA might point to a role for HPyV6 in the
etiopathogenesis of KAs. It would be highly interesting
to test a larger number of Vemurafenib induced KAs
and SCCs for the presence of HPyV6. In addition,
HPyV6 might play a role in the carcinogenesis of a sig-
nificant subset of BCC and TB.
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